---
title: "Xtant Medical Gains Exclusive U.S. Rights to HEMOBLAST Bellows, Pays $5.0M Fee"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282552865.md"
description: "Xtant Medical has secured exclusive U.S. distribution rights for HEMOBLAST Bellows, paying a $5.0 million fee to Dilon. The agreement allows Xtant to import, market, and sell the product in the U.S., with Dilon continuing manufacturing in France. Xtant has hired approximately 20 former Dilon sales personnel to aid in commercialization. The company plans to update its full-year 2026 financial guidance in conjunction with Q1 2026 results due to this new arrangement."
datetime: "2026-04-13T13:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282552865.md)
  - [en](https://longbridge.com/en/news/282552865.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282552865.md)
---

# Xtant Medical Gains Exclusive U.S. Rights to HEMOBLAST Bellows, Pays $5.0M Fee

**Xtant Medical announced exclusive U.S. distribution rights for HEMOBLAST Bellows and paid a $5.0 million exclusivity fee.**

**Key Highlights:**

-   Entered Distribution Agreement with Dilon to exclusively import, market, distribute and sell HEMOBLAST Bellows in the U.S.
-   Paid a $5.0 million exclusivity fee to Dilon, refundable under certain termination circumstances.
-   Hired ~20 former Dilon U.S. sales personnel to support U.S. commercialization and transition existing U.S. customer contracts.
-   Dilon will continue manufacturing in France and supply product to Xtant at a transfer price subject to contract terms; no minimum purchase requirements.
-   Xtant plans to update full-year 2026 financial guidance alongside Q1 2026 results due to the new distribution arrangement.

Original SEC Filing: Xtant Medical Holdings, Inc. \[ XTNT \] - 8-K - Apr. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [XTNT.US](https://longbridge.com/en/quote/XTNT.US.md)

## Related News & Research

- [Xtant Medical Reports First Quarter 2026 Financial Results | XTNT Stock News](https://longbridge.com/en/news/286247087.md)
- [Xtant Medical Updates Q1 Results and Raises 2026 Guidance](https://longbridge.com/en/news/286254004.md)
- [Herbal Dispatch Completes Company Record 500kg Medical Cannabis Export Shipment to Europe | LUFFF Stock News](https://longbridge.com/en/news/286883156.md)
- [How Investors May Respond To American Healthcare REIT (AHR) Cutting 2026 Profit Outlook After Q1 Results](https://longbridge.com/en/news/286866277.md)
- [Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase | AKTX Stock News](https://longbridge.com/en/news/286776452.md)